Brian Jurewitsch

Dr. Brian Jurewitsch


Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 April 2013 in Journal of Parenteral and Enteral Nutrition
Verified
Journal Article
Open access
PDF file
WMWilliam Manzanares
William Manzanares
RDRupinder Dhaliwal
Rupinder Dhaliwal
BJBrian Jurewitsch
Brian Jurewitsch
RSRenee D. Stapleton
Renee D. Stapleton
KJKhursheed N. Jeejeebhoy
Khursheed N. Jeejeebhoy
Daren HeylandDaren Heyland
Daren Heyland
Introduction: ω‐3 Polyunsaturated fatty acids contained in fish oils (FO) possess major anti‐inflammatory, antioxidant, and immunologic properties that could be beneficial during critical illness. We hypothesized that parenteral FO‐containing emulsions may improve clinical outcomes in the critically ill. Methods: We searched computerized databases from 1980–2012. We included randomized controlled trials (RCTs) conducted in critically ill adult patients that evaluated FO‐containing emulsions, either in the context of parenteral nutrition (PN) or enteral nutrition (EN). Results: A total of 6 RCTs (n = 390 patients) were included; the mean methodological score of all trials was 10 (range, 6–13). When the results of these studies were aggregated, FO‐containing emulsions were associated with a trend toward a reduction in mortality (risk ratio [RR], 0.71; 95% confidence interval [CI], 0.49–1.04; P = .08; heterogeneity I2 = 0%) and a reduction in the duration of mechanical ventilation (weighted mean difference in days [WMD], −1.41; 95% CI, −3.43 to 0.61; P = .17). However, this strategy had no effect on infections (RR, 0.76; 95% CI, 0.42–1.36; P = .35) and intensive care unit length of stay (WMD, −0.46; 95% CI, −4.87 to 3.95; P = .84, heterogeneity I2 = 75%). Conclusion: FO‐containing lipid emulsions may be able to decrease mortality and ventilation days in the critically ill. However, because of the paucity of clinical data, there is inadequate evidence to recommend the routine use of parenteral FO. Large, rigorously designed RCTs are required to elucidate the efficacy of parenteral FO in the critically ill.

29 June 2013 in Intensive Care Medicine
Verified
Journal Article
Closed access
PDF file
WMWilliam Manzanares
William Manzanares
RDRupinder Dhaliwal
Rupinder Dhaliwal
BJBrian Jurewitsch
Brian Jurewitsch
RSRenee D. Stapleton
Renee D. Stapleton
KJKhursheed N. Jeejeebhoy
Khursheed N. Jeejeebhoy
Daren HeylandDaren Heyland
Daren Heyland

28 April 2011 in Journal of Parenteral and Enteral Nutrition
Verified
Journal Article
Closed access
BJBrian Jurewitsch
Brian Jurewitsch
GGGeoffrey Gardiner
Geoffrey Gardiner
MNMark Naccarato
Mark Naccarato
KJKhursheed N. Jeejeebhoy
Khursheed N. Jeejeebhoy

5 August 2025 in BMJ Open Gastroenterology
Verified
Journal Article
Open access
PDF file
BJBrian Jurewitsch
Brian Jurewitsch
CPColette Peters
Colette Peters
COCarol Okamoto
Carol Okamoto
Objective: This study aimed to explore the lived experiences and coping strategies of patients with short bowel syndrome (SBS) prescribed teduglutide and weaning off home parenteral nutrition (HPN), and to compare the quality of life (QOL) of these patients to patients with SBS but not prescribed teduglutide. Methods: A qualitative study was conducted, with patients recruited from a specialist HPN clinic. Participants completed handwritten semi-structured daily diaries for 6 weeks and a validated Home Parenteral Nutrition-Quality of Life (HPN-QOL) paper-based questionnaire as part of what aimed to be a mixed methods cross-tracks study. Participants were age-matched with patients with SBS receiving HPN but not prescribed teduglutide, and these ‘controls’ also completed the HPN-QOL questionnaire. Data analysis involved qualitative analysis of diary entries using grounded theory methodology and descriptive analysis of HPN-QOL questionnaire responses. Results: Five participants completed the study and were matched with four ‘controls’. All participants and ‘controls’ reported a high QOL with no differences observed between patients prescribed and not prescribed teduglutide. Qualitative analysis revealed that participants engaged in iterative cycles of problem-focused action and emotion-focused coping strategies to manage their condition and wean off parenteral nutrition (PN). Key subthemes included polyphagia and pleomorphism in diet, fatigue-related emotional distress and positive reframing using an objective scientific lens. Decisional regret was absent, participants agreed that treatment with teduglutide was the right choice for them, despite its challenges. Their goal of independence from PN was the main motivating factor. Conclusion: This study provides valuable insights into the lived experiences and coping strategies of patients with SBS prescribed teduglutide to wean off PN. The findings underscore the importance of healthcare teams understanding these everyday challenges to facilitate shared decision-making and tailor care plans. Further research is needed to explore the long-term impact of teduglutide on QOL, including the validation of tools to screen for fatigue-related emotional distress and the development of targeted interventions to support patients during the weaning process.